TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Trial Investigating the Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette) in Smokers
Brief Summary: The study's major aim is to investigate the ability of a commercial Electronic Nicotine Delivery Device (E-Cigarette) to induce long-term smoking reduction/abstinence in smokers unwilling to quit. Secondary aims are to investigate changes in withdrawal symptoms and cravings and to examine whether concomitant use of the E-Cigarette and smoking is safe.

The study will monitor smoking reduction/abstinence effects, changes in withdrawal symptoms, and adverse events of a currently marketed device in Italy ("Categoria" electronic cigarette - "ORIGINAL" 7.2 mg nicotine cartridges).

The primary hypothesis is that the E-Cigarette is a safe device that allows smoking reduction or abstinence in smokers possibly by suppressing withdrawal symptoms and cravings.


Options:
A: Arm Label: HIGH NICOTINE; Type: N/A; Interventions: N/A
B: Arm Label: Scheduled Gradual Reduction (SGR); Type: EXPERIMENTAL; Interventions: Behavioral: SGR, Behavioral: Support message only | Arm Label: Support Message Only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support message only | Intervention Type: BEHAVIORAL; Name: SGR; Assigned to Arm(s): Scheduled Gradual Reduction (SGR) | Intervention Type: BEHAVIORAL; Name: Support message only; Assigned to Arm(s): Scheduled Gradual Reduction (SGR), Support Message Only
C: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Swedish snus (smokeless tobacco) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Onico | Intervention Type: OTHER; Name: Swedish snus (smokeless tobacco); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Onico; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Trial Investigating the Efficacy and Safety of an Electronic Nicotine Delivery Device (E-Cigarette) in Smokers
Brief Summary: The study's major aim is to investigate the ability of a commercial Electronic Nicotine Delivery Device (E-Cigarette) to induce long-term smoking reduction/abstinence in smokers unwilling to quit. Secondary aims are to investigate changes in withdrawal symptoms and cravings and to examine whether concomitant use of the E-Cigarette and smoking is safe.

The study will monitor smoking reduction/abstinence effects, changes in withdrawal symptoms, and adverse events of a currently marketed device in Italy ("Categoria" electronic cigarette - "ORIGINAL" 7.2 mg nicotine cartridges).

The primary hypothesis is that the E-Cigarette is a safe device that allows smoking reduction or abstinence in smokers possibly by suppressing withdrawal symptoms and cravings.


Options:
A: Arm Label: Nicotine; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking cessation program TFC and activity tracker | Arm Label: Nicotine-free; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation program TFC-free and activity tracker | Arm Label: No-cig; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation program and activity tracker | Intervention Type: BEHAVIORAL; Name: Smoking cessation program TFC and activity tracker; Assigned to Arm(s): Nicotine | Intervention Type: BEHAVIORAL; Name: Smoking cessation program TFC-free and activity tracker; Assigned to Arm(s): Nicotine-free | Intervention Type: BEHAVIORAL; Name: Smoking cessation program and activity tracker; Assigned to Arm(s): No-cig
B: Arm Label: E-cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Traditional cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Mixed group; Type: N/A; Interventions: N/A
C: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator
D: Arm Label: HIGH NICOTINE; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gender Differences in the Development and Prognosis of Coronary Disease Where Initial Disease Manifestation is Stable Angina, Myocardial Infarction or Unheralded Coronary Death: A CALIBER Study Using Linked GPRD-MINAP Data
Brief Summary: The initial manifestation of symptomatic coronary disease can range from angina (or symptoms of angina), unheralded acute coronary syndrome (ACS), or unheralded coronary death. A better understanding of gender differences in initial presentation of coronary disease and the rate and predictors of progression to subsequent stages in coronary disease could help to identify which gender- specific factors might reduce or slow transition to more serious disease states and improve outcomes. The investigators' research focuses on the role primary care management of cardiovascular risk factors plays in gender differences in the progression to subsequent disease states and to mortality.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Device: ambulatory blood pressure monitoring | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ramipril, Device: ambulatory blood pressure monitoring | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): 1, 2 | Intervention Type: DEVICE; Name: ambulatory blood pressure monitoring; Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Any antihypertensive medication alone or in combination, Device: Ambulatory blood pressure monitoring | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Any antihypertensive medication alone or in combination, Device: Ambulatory blood pressure monitoring | Intervention Type: DRUG; Name: Any antihypertensive medication alone or in combination; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Any antihypertensive medication alone or in combination; Assigned to Arm(s): 2 | Intervention Type: DEVICE; Name: Ambulatory blood pressure monitoring; Assigned to Arm(s): 1, 2
C: Arm Label: Initial presentation of coronary disease - Stable angina; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - ACS; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - Coronary death; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - None; Type: N/A; Interventions: N/A
D: Intervention Type: DRUG; Name: valsartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gender Differences in the Development and Prognosis of Coronary Disease Where Initial Disease Manifestation is Stable Angina, Myocardial Infarction or Unheralded Coronary Death: A CALIBER Study Using Linked GPRD-MINAP Data
Brief Summary: The initial manifestation of symptomatic coronary disease can range from angina (or symptoms of angina), unheralded acute coronary syndrome (ACS), or unheralded coronary death. A better understanding of gender differences in initial presentation of coronary disease and the rate and predictors of progression to subsequent stages in coronary disease could help to identify which gender- specific factors might reduce or slow transition to more serious disease states and improve outcomes. The investigators' research focuses on the role primary care management of cardiovascular risk factors plays in gender differences in the progression to subsequent disease states and to mortality.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Myocardial fibrosis, outcomes; Type: N/A; Interventions: N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: n-3 PUFA | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: n-3 PUFA; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: Initial presentation of coronary disease - Stable angina; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - ACS; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - Coronary death; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - None; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Gender Differences in the Development and Prognosis of Coronary Disease Where Initial Disease Manifestation is Stable Angina, Myocardial Infarction or Unheralded Coronary Death: A CALIBER Study Using Linked GPRD-MINAP Data
Brief Summary: The initial manifestation of symptomatic coronary disease can range from angina (or symptoms of angina), unheralded acute coronary syndrome (ACS), or unheralded coronary death. A better understanding of gender differences in initial presentation of coronary disease and the rate and predictors of progression to subsequent stages in coronary disease could help to identify which gender- specific factors might reduce or slow transition to more serious disease states and improve outcomes. The investigators' research focuses on the role primary care management of cardiovascular risk factors plays in gender differences in the progression to subsequent disease states and to mortality.


Options:
A: Arm Label: Intensive BP treatment arm; Type: EXPERIMENTAL; Interventions: Other: Treatment strategy regarding different systolic BP goals | Arm Label: Standard BP treatment arm; Type: OTHER; Interventions: Other: Treatment strategy regarding different systolic BP goals | Intervention Type: OTHER; Name: Treatment strategy regarding different systolic BP goals; Assigned to Arm(s): Intensive BP treatment arm, Standard BP treatment arm
B: Arm Label: Aggressive Blood Pressure control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aggressive Blood Pressure control | Arm Label: Standard Blood Pressure control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Aggressive Blood Pressure control; Assigned to Arm(s): Aggressive Blood Pressure control
C: Arm Label: The intensive care group; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine 5mg, Drug: Losartan, Drug: Losartan and Amlodipine, Drug: Amlodipine/Losartan/Chlorthalidone | Arm Label: The usual care group; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine 5mg, Drug: Losartan, Drug: Losartan and Amlodipine, Drug: Amlodipine/Losartan/Chlorthalidone, Drug: current treatment | Intervention Type: DRUG; Name: Amlodipine 5mg; Assigned to Arm(s): The intensive care group, The usual care group | Intervention Type: DRUG; Name: Losartan; Assigned to Arm(s): The intensive care group, The usual care group | Intervention Type: DRUG; Name: Losartan and Amlodipine; Assigned to Arm(s): The intensive care group, The usual care group | Intervention Type: DRUG; Name: Amlodipine/Losartan/Chlorthalidone; Assigned to Arm(s): The intensive care group, The usual care group | Intervention Type: DRUG; Name: current treatment; Assigned to Arm(s): The usual care group
D: Arm Label: Initial presentation of coronary disease - Stable angina; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - ACS; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - Coronary death; Type: N/A; Interventions: N/A | Arm Label: Initial presentation of coronary disease - None; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HZA106827: A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Parallel Group Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Brief Summary: The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 12 week treatment period.


Options:
A: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder | Arm Label: Fluticasone Furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaltion Powder | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Placebo Inhaltion Powder; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: GW685698X; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): GW685698X | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: LABA; Type: EXPERIMENTAL; Interventions: Drug: GW642444 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GW642444; Assigned to Arm(s): LABA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/Vilanterol Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Furoate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Furoate Inhalation Powder, Other: Placebo Inhalation Powder 2 | Arm Label: Fluticasone Propionate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Propionate Inhalation Powder, Other: Placebo Inhalation Powder 1 | Intervention Type: DRUG; Name: Fluticasone Furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Fluticasone Propionate Inhalation Powder; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 1; Assigned to Arm(s): Fluticasone Propionate | Intervention Type: OTHER; Name: Placebo Inhalation Powder 2; Assigned to Arm(s): Fluticasone Furoate, Fluticasone Furoate/Vilanterol

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HZA106827: A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Parallel Group Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Brief Summary: The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 12 week treatment period.


Options:
A: Arm Label: tiotropium 5 mcg; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 5 mcg | Arm Label: tiotropium 2.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 2.5 mcg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: tiotropium 2.5 mcg; Assigned to Arm(s): tiotropium 2.5 mcg | Intervention Type: DRUG; Name: tiotropium 5 mcg; Assigned to Arm(s): tiotropium 5 mcg
B: Arm Label: Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flutiform, Drug: Symbicort Turbohaler | Arm Label: inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Symbicort Turbohaler | Intervention Type: DRUG; Name: Flutiform; Assigned to Arm(s): Inhaler | Intervention Type: DRUG; Name: Symbicort Turbohaler; Assigned to Arm(s): Inhaler, inhaler
C: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate, Drug: Vilanterol | Arm Label: FP/S OR BUD/F; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate, Drug: Salmeterol, Drug: Budesonide, Drug: Formoterol Fumarate | Intervention Type: DRUG; Name: Fluticasone Furoate; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Vilanterol; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): FP/S OR BUD/F | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): FP/S OR BUD/F | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): FP/S OR BUD/F | Intervention Type: DRUG; Name: Formoterol Fumarate; Assigned to Arm(s): FP/S OR BUD/F
D: Arm Label: Fluticasone furoate/Vilanterol (GW642444); Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate/Vilanterol Inhalation Powder | Arm Label: Fluticasone Furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Inhaltion Powder | Intervention Type: DRUG; Name: Fluticasone furoate/Vilanterol Inhalation Powder; Assigned to Arm(s): Fluticasone furoate/Vilanterol (GW642444) | Intervention Type: DRUG; Name: Fluticasone Furoate Inhalation Powder; Assigned to Arm(s): Fluticasone Furoate | Intervention Type: DRUG; Name: Placebo Inhaltion Powder; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older
Brief Summary: The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 70 years.

Two studies (Zoster-006 \[NCT01165177\] and Zoster-022 \[NCT01165229\]) will be conducted concurrently to evaluate efficacy of GSK1437173A vaccine. A pooled analysis of data from both studies combined will be conducted contingent on each study achieving its objectives. This protocol posting also deals with the outcome measures related to the pooled analysis.


Options:
A: Arm Label: SC HZ/su Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: IM HZ/su Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Intervention Type: BIOLOGICAL; Name: Herpes zoster vaccine GSK1437173A; Assigned to Arm(s): IM HZ/su Group, SC HZ/su Group
B: Arm Label: Concomitant Vaccination; Type: EXPERIMENTAL; Interventions: Biological: ZOSTAVAX™, Biological: Placebo to ZOSTAVAX™, Biological: Influenza Vaccine | Arm Label: Nonconcomitant Vaccination; Type: EXPERIMENTAL; Interventions: Biological: ZOSTAVAX™, Biological: Placebo to ZOSTAVAX™, Biological: Influenza Vaccine | Intervention Type: BIOLOGICAL; Name: ZOSTAVAX™; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination | Intervention Type: BIOLOGICAL; Name: Placebo to ZOSTAVAX™; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination | Intervention Type: BIOLOGICAL; Name: Influenza Vaccine; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination
C: Arm Label: Zoster vaccine group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster Vaccine GSK1437173A | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes Zoster Vaccine GSK1437173A; Assigned to Arm(s): Zoster vaccine group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo group
D: Arm Label: GSK1437173A group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster Vaccine GSK1437173A | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Herpes Zoster Vaccine GSK1437173A; Assigned to Arm(s): GSK1437173A group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Active Controlled, Optimal Dose Titration, Multicenter Study to Evaluate the Safety and Efficacy of Oral JNS024 Extended Release (ER) in Japanese and Korean Subjects With Moderate to Severe Chronic Malignant Tumor Related Cancer Pain
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of R331333 (referred to as JNS024 Extended-Release (ER) or CG5503) compared with an active comparator (oxycodone Controlled Release (CR)) in Japanese and Korean patients with chronic, malignant, tumor-related cancer pain.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: R331333 (referred to as JNS024 ER or CG5503) | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR | Intervention Type: DRUG; Name: Oxycodone CR; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: R331333 (referred to as JNS024 ER or CG5503); Assigned to Arm(s): 001
B: Arm Label: carboplatin + etoposide + exisulind; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: etoposide, Drug: exisulind | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): carboplatin + etoposide + exisulind | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): carboplatin + etoposide + exisulind | Intervention Type: DRUG; Name: exisulind; Assigned to Arm(s): carboplatin + etoposide + exisulind
C: Arm Label: Oxycodone Hydrochloride Tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone | Arm Label: Oxycodone Naloxone Tablets; Type: EXPERIMENTAL; Interventions: Drug: Oxycodone/Naloxone | Intervention Type: DRUG; Name: Oxycodone; Assigned to Arm(s): Oxycodone Hydrochloride Tablets | Intervention Type: DRUG; Name: Oxycodone/Naloxone; Assigned to Arm(s): Oxycodone Naloxone Tablets
D: Arm Label: The LCP-I Program.; Type: EXPERIMENTAL; Interventions: Other: The LCP-I Program | Arm Label: standard healthcare practices; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: The LCP-I Program; Assigned to Arm(s): The LCP-I Program.

Answer: A